The Technical Analyst
Tyme Technologies, Inc. [TYME]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Biotechnology
Tyme Technologies, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
8.07% $0.311
/ 16 sep 2022 @ 16:00
| RATING 2022-09-16 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.27 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.27 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.286 - 0.336 ( +/- 8.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-09-16 | Hoffman Steve | Sell | 20 022 566 | Common Stock |
| 2022-09-16 | Hoffman Steve | Sell | 88 000 | Director Stock Option - Option to buy |
| 2022-09-16 | Tyson Timothy | Sell | 5 865 | Common Stock |
| 2022-09-16 | Tyson Timothy | Sell | 50 058 | Director Stock Option - Option to buy |
| 2022-09-16 | Tyson Timothy | Sell | 25 000 | Director Stock Option - Option to buy |
| INSIDER POWER |
|---|
| -90.28 |
| Last 99 transactions |
| Buy: 4 624 822 | Sell: 25 464 364 |
Forecast:
01:40 - $0.295
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.311 (8.07% ) |
| Volume | 2.68 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TYME
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TYME
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
Last 10 Buy Signals
Latest Press Releases
2022-07-06 11:23:00 - Press Release
Shareholder Alert: Rigrodsky Law, P.a. Is Investigating Tyme Technologies, Inc. Merger
Wilmington, delaware--(newsfile corp. - july 6, 2022) - rigrodsky law, p.a. is investigating tyme technologies, inc. ("tyme") (nasdaq: tyme) regarding possible breaches of fiduciary duties and other violations of law related to tyme's agreement to be acquired by syros pharmaceuticals, inc. ("syros") (nasdaq: syrs). under the terms of the agreement, tyme's shareholders will receive approximately 0.4312 shares of syros common stock for each share of tyme common stock they own.to learn more about this investigation...
2022-07-05 20:50:00 - Press Release
Shareholder Alert: Weiss Law Investigates Syros Pharmaceuticals, Inc.
New york , july 5, 2022 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of syros pharmaceuticals, inc. ("syros" or the "company") (nasdaq: syrs) in connection with the proposed merger of the company with tyme technologies, inc. ("tyme") (nasdaq: tyme). under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one combined entity that will continue to trade publicly on the nasdaq under the ticker symbol "syrs.
2022-07-05 07:00:00 - Press Release
Syros To Raise Approximately $190 Million Through Merger With Tyme Technologies And Concurrent Private Placement
Cambridge, mass. & bedminster, n.j.--(business wire)--syros pharmaceuticals (nasdaq:syrs), a leader in the development of medicines that control the expression of genes, and tyme technologies, inc. (nasdaq:tyme), today announced that the companies have entered into a definitive merger agreement pursuant to which syros will acquire tyme, including its pipeline assets and net cash at closing which after accounting for wind-down and transaction expenses is currently estimated to be approximately $
2022-01-27 16:30:00 - Press Release
Tyme Technologies, Inc. To Host Conference Call And Webcast On Friday, February 11, At 8:30 Am Et
Bedminster, n.j.--(business wire)--tyme technologies, inc. (nasdaq: tyme) (the “company” or “tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (cmbts™), today announced that the company will report its third quarter 2022 financial results on friday, february 11, 2022, at 8:30 am et. richie cunningham, chief executive officer, and frank porfido, chief financial officer, will host a conference call and webcast as follows: date: friday, february 11, 2022 time: 8:30 am et toll-free (u.s.) (866) 601-3896 international (636) 812-6499 conference id 1286376 the webcast will be accessible on the events & presentations page of the investors section of the tyme website, tymeinc...
2021-11-02 17:30:00 - Press Release
Tyme Technologies, Inc. To Present At Jefferies London Healthcare Conference
Bedminster, n.j.--(business wire)--tyme technologies, inc. (nasdaq: tyme) (the company or tyme), an emerging biotechnology company developing cancer metabolism-based therapies (cmbts™), today announced that richie cunningham, chief executive officer, and jonathan eckard, chief business officer, will present at the jefferies london healthcare conference as follows: date: wednesday, november 17, 2021 time: 1:40 pm greenwich mean time / 8:40 am eastern standard time webcast:
Latest News
2022-07-05 09:15:11 - PennyStocks
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-05 08:16:03 - Benzinga
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million. Syros expects to issue.
2022-05-26 11:35:35 - Seeking Alpha
Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives.
2022-03-29 08:01:35 - Market Watch
Tyme Technologies shares jump premarket on news board to explore strategic options
Tyme Technologies Inc. TYME, -5.56% , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a financial adviser and Faegre Drinker Biddle & Reath LLP as its legal adviser. The move comes after the Bedminster, New Jersey-based company had to discontinue a Phase 2/3 trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer after the trial sponsor terminated the study arm due to futility.
2022-02-11 10:22:04 - Seeking Alpha
Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript
Tyme Technologies, Inc.'s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript
2021-12-30 00:35:12 - Pulse2
Tyme Technologies Stock (TYME): Why The Price Fell
The stock price of Tyme Technologies Inc (NASDAQ: TYME) fell by 1.66% in the most recent trading session. This is why it happened.
2021-12-07 18:47:02 - Seeking Alpha
Tyme Technologies Offers Incredible Risk-Reward
Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices.
2021-11-08 11:08:03 - Seeking Alpha
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q2 2021 Results - Earnings Call Transcript
2021-11-02 17:30:00 - Business Wire
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the Jefferies London Healthcare Conference as follows: Date: Wednesday, November 17, 2021 Time: 1:40 PM Greenwich Mean Time / 8:40 AM Eastern Standard Time Webcast:
2021-09-27 06:50:00 - Business Wire
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (“TYME” or the “Company”) (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first patient has been dosed in the Phase II OASIS trial in patients with metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who previously received a CDK4/6 inhibitor regimen being conducted by Georgetown University (N